SEC Form 4 · accession 0001380178-15-000003
AGENUS INC · AGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shahzad Malik
Director
Period of report
May 27, 2015
Accepted (ET)
May 27, 2015 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001098972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 27, 2015 | J | 1,587,302 | $6.30 | A | 1,587,302 | I | see footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Advent Life Sciences LLP and Advent Life Sciences Fund II LP acquired 54,556 and 1,532,746 shares of Agenus Inc. common stock, respectively, in a public offering that closed on May 27, 2015. Advent Life Sciences LLP is the General Partner of Advent Life Sciences Fund II LP. Dr. Malik is a General Partner of Advent Life Sciences LLP and shares voting and investment power over the shares, and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.